Genetics Institute, Inc.

USA As Represented by Secretary of the Navy

University of Michigan

Dana-farber-cancer Institute Inc.

Other

Repligen Corporation

Lubrizol Advanced Materials, Inc.

Replingen Corporation

Gary S Gray

Paul David Rennert

Gordon James Freeman

Carl H June

Gary J Nabel

Craig B Thompson

Lee M Nadler

Mary Collins

Beatriz M Carreno

Denise M O'Hara

Maximiliano Vasquez

Geertruida Machteld Veldman

Samuel Goldman

Man Sung Co

Abbie Cheryl Celniker

Andrea Knight

Bonita Rup

Edward Alvin Greenfield

Cindy L Jellis

Krishnan Tamareselvy

Deborah S Filla

Kashi Javaherian

John G Gribben

Jerry Carson

Sandra Silver

Naoya Tsurushita

John J Mullay

Clive R Wood

William F Masler, Iii

Paul Robert Hinton

James C Keith, Jr

Katherine Jane Turner

Vincent Ling

Yi Yang

Steven J Smith

David L Dashiell

Srinivas Maganti

Donna Morris

William F Iii Masler

Disclosed are multi-staged acrylic based core-shell polymers comprising a linear core polymer and at least one subsequently polymerized shell polymers is crosslinked. The core-shell polymers surprisingly provide desirable rheological, clarity, and aesthetic properties in aqueous surfactant containing compositions, particularly at low pH.

Structured acrylate copolymer thickeners

A method for increasing the efficacy of hydrophobically modified (meth)acrylic based polymers to increase the critical micelle concentration of a surfactant composition by attenuating the degree of neutralization (DN) of the polymer is disclosed.

Irritation mitigating polymers and uses therefor

The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Methods of treatment of autoimmune diseases using humanized immunoglobulin reactive with B7-2

Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an epitope of CTLA4 distinct from the binding sites of B7-1 and B7-2. Upon binding of the antibody to CTLA4 on an activated T cell, in the presence of an antigenic signal, antigen specific apoptosis is induced. The invention also describes a novel natural CTLA4 ligand, distinct from B7-1 and B7-2, which mediates induction of apoptosis. Pharmaceutical compositions of anti-CTLA4 antibodies or other isolated CTLA4 ligands which can be administered to subjects to induce T cell apoptosis, thereby clonally deleting antigen specific T cells, such as alloreactive T cells in transplantation situations or autoreactive T cells in autoimmune disorders, are also disclosed. Methods for inducing T cell apoptosis in vitro with an anti-CTLA4 antibody or other ligand of the invention together with an antigen specific signal are also disclosed, e.g., for use in purging alloreactive T cells from donor bone marrow prior to bone marrow transplantation to inhibit graft versus host disease.

Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies

The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules

Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

Methods for selectively enriching TH1 and TH2 cells

Nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the nucleic acid has a sequence which encodes a B lymphocyte antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a portion of a nucleotide sequence shown in FIG., SEQ ID NO:1 or FIG., SEQ ID NO:23. The nucleic acid sequences of the invention can be integrated into various expression vectors, which in turn direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also disclosed are host cells transformed to produce proteins or peptides encoded by the nucleic acid sequences of the invention and isolated proteins and peptides which comprise at least a portion of a novel B lymphocyte antigen. Proteins and peptides described herein can be administered to subjects to enhance or suppress T cell-mediated immune responses.

Nucleic acids encoding B7-2 fusion proteins

Methods for treating HIV infected subjects

Methods for selectively stimulating proliferation of T cells

The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The invention further provides anti-CTLA4 antibodies and humanized forms thereof.

Antibodies against CTLA4

Method of transplanting cells by contacting donor cells with B7-1-and B7-2-specific immunoglobulins

Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith

Humanized immunoglobulin reactive with B7 therewith

Growing community of inventors

Brookline, MA, United States of America

Gary S Gray